通过低剂量复合人体生长激素疗法达到最佳的成年终身高
Tansit Saengkaew1,2, Suparb Aroonparkmongkol1, Suttipong Wacharasindhu1
1Division of Endocrinology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Asian biomedicine : research, reviews and news
|May 6, 2024
概括
低剂量重组人体生长激素 (rhGH) 治疗有效帮助儿童达到最佳的最终成年身高 (FAH). 患有多发性垂体激素缺乏症 (MPHD) 的患者往往会在成年后持续患有生长激素缺乏症 (GHD).
科学领域:
- 儿科内分泌学 儿科内分泌学
- 激素治疗是一种激素治疗.
- 增长障碍 发展障碍 发展障碍
背景情况:
- 复合人体生长激素 (rhGH) 在泰国已经使用了20多年.
- 由于资源有限,需要使用最低可行的rhGH剂量.
- 关于低剂量rhGH疗效和结果的证据有限.
研究的目的:
- 评估生长激素 (GH) 治疗的外科医疗结果.
- 在达到最终成年人身高 (FAH) 和停止服用rhGH后评估GH分泌能力.
主要方法:
- 对40名患者的数据进行回顾性审查.
- 临床特征的评价,耳学数据和内分泌研究.
- 在24名患者中使用胰岛素耐受性测试进行GH重复测试.
主要成果:
- 50%的患者有完全的生长激素缺乏 (GHD);其他人有部分的GHD.
- 部分GHD患者比完全GHD患者获得更高的rhGH剂量.
- 良好的身高增长的因素包括GH峰值,青春期年龄和rhGH停止年龄. 13/24患者在治疗后显示正常的GH分泌. 88.9%的MPHD患者患有持续的GHD.
结论:
- 低剂量的rhGH可以导致儿童的最佳FAH.
- 患有MPHD的患者可能有持续的GHD,可能不需要重新测试.
- 这些发现支持在资源有限的环境中使用rhGH.
相关概念视频
Nature and Nurture
20.5K
Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
20.5K
Polygenic Traits
65.7K
When more than one gene is responsible for a given phenotype, the trait is considered polygenic. Human height is a polygenic trait. Studies have uncovered hundreds of loci that influence height, and there are believed to be many more. Due to the high number of genes involved, as well as environmental and nutritional factors, height varies significantly within a given population. The distribution of height forms a bell-shaped curve, with relatively few individuals in the population at the...
65.7K
Signs of Puberty
331
Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
331
Hormones and Bone Tissue
2.7K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
2.7K
Insulin: Dosing Regimen and Adverse Effects
167
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
167
Hypoglycemia and Glucagon
257
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
257


